Dynavax begins Phase II/III

Dynavax (Berkeley, Calif.) began a placebo-controlled U.S. Phase II/III trial of its Amb a 1 immunostimulatory conjugate (AIC) to treat ragweed allergies. The 40-patient trial will compare inflammator...